Table 4.

Multivariate regression models for association between non-permissive DPB1 TCE 3/ DPA1 allele mismatches and clinical outcome.

	Permissive HLA-DPB1 mismatch + DPA1 match (N = 321)	Permissive HLA-DPB1 mismatch + DPA1 mismatch (N = 264)		HLA-DPB1 match + HLA- DPA1 match (N = 229)		HLA-DPB1 match + HLA- DPA1 mismatch (N=10)		Non-Permissive HLA-DPB1 mismatch + HLA-DPA1 match (N = 219)		Non-Permissive HLA-DPB1 mismatch + HLA-DPA1 mismatch (N = 238)
	Ref.	HR (95% CI)	p- value	HR (95% CI)	p- value	HR (95% CI)	p- value	HR (95% CI)	p- value	HR (95% CI)	p- value
Overall mortalitya	1	0.92 (0.75–1.13)	0.42	0.87 (0.71–1.08)	0.22	2.31 (1.22–4.41)	0.011	1.22 (0.99–1.50)	0.06	1.03 (0.84–1.27)	0.76
Treatment-related mortalityb	1	1.01 (0.78–1.31)	0.93	0.84 (0.63–1.10)	0.2	1.97 (0.86–4.50)	0.11	1.39 (1.08–1.78)	0.01	1.19 (0.93–1.53)	0.16
Relapsec	1	0.74 (0.54–1.04)	0.08	1.13 (0.83–1.54)	0.44	2.70 (0.981–7.39)	0.05	0.84 (0.59–1.19)	0.33	0.62 (0.43–0.89)	0.01
aGVHD C–Dd	1	1.11 (0.83–1.49)	0.49	1.00 (0.74–1.37)	0.98	1.02 (0.32–3.21)	0.98	1.22 (0.90–1.66)	0.19	1.42 (1.06–1.89)	0.02

^aadjusted for disease, disease status, GVHD prophylaxis, use of in vivo T cell depletion, preparative regimen, and recipient age at transplant.

^badjusted for disease status, GVHD prophylaxis, use of in vivo T cell depletion, preparative regimen and recipient age at transplant.

^cadjusted for disease and disease status.

^dadjusted for disease, disease status, graft type and year of transplant.